The stock of Xilio Therapeutics Inc (XLO) has gone down by -6.96% for the week, with a 2.88% rise in the past month and a 41.20% rise in the past quarter. The volatility ratio for the week is 11.52%, and the volatility levels for the past 30 days are 12.88% for XLO. The simple moving average for the past 20 days is 4.18% for XLO’s stock, with a 8.98% simple moving average for the past 200 days.
Is It Worth Investing in Xilio Therapeutics Inc (NASDAQ: XLO) Right Now?
Company’s 36-month beta value is -0.22.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for XLO is 18.77M, and currently, short sellers hold a 0.64% ratio of that floaft. The average trading volume of XLO on January 03, 2025 was 468.12K shares.
XLO) stock’s latest price update
The stock price of Xilio Therapeutics Inc (NASDAQ: XLO) has jumped by 12.04 compared to previous close of 0.95. Despite this, the company has seen a fall of -6.96% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities
Analysts’ Opinion of XLO
Many brokerage firms have already submitted their reports for XLO stocks, with Chardan Capital Markets repeating the rating for XLO by listing it as a “Buy.” The predicted price for XLO in the upcoming period, according to Chardan Capital Markets is $7 based on the research report published on December 21, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XLO reach a price target of $36. The rating they have provided for XLO stocks is “Buy” according to the report published on January 10th, 2022.
Raymond James gave a rating of “Outperform” to XLO, setting the target price at $31 in the report published on November 16th of the previous year.
XLO Trading at 2.42% from the 50-Day Moving Average
After a stumble in the market that brought XLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.56% of loss for the given period.
Volatility was left at 12.88%, however, over the last 30 days, the volatility rate increased by 11.52%, as shares surge +4.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.10% upper at present.
During the last 5 trading sessions, XLO fell by -6.96%, which changed the moving average for the period of 200-days by +57.65% in comparison to the 20-day moving average, which settled at $1.0272. In addition, Xilio Therapeutics Inc saw 12.04% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XLO starting from GILEAD SCIENCES, INC., who purchase 1,759,978 shares at the price of $1.04 back on Dec 18 ’24. After this action, GILEAD SCIENCES, INC. now owns 9,105,451 shares of Xilio Therapeutics Inc, valued at $1,830,377 using the latest closing price.
GILEAD SCIENCES, INC., the 10% Owner of Xilio Therapeutics Inc, purchase 485,250 shares at $0.76 during a trade that took place back on Apr 02 ’24, which means that GILEAD SCIENCES, INC. is holding 7,345,473 shares at $368,790 based on the most recent closing price.
Stock Fundamentals for XLO
Current profitability levels for the company are sitting at:
- -8.52 for the present operating margin
- 0.82 for the gross margin
The net margin for Xilio Therapeutics Inc stands at -8.35. The total capital return value is set at -1.75. Equity return is now at value -170.96, with -82.36 for asset returns.
Currently, EBITDA for the company is -73.8 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of -0.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In a nutshell, Xilio Therapeutics Inc (XLO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
